Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Potentiation of in vitro and in vivoantitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells

Figure 5

The combination treatment of doxorubicin with P276-00 showed significant tumor growth inhibition in H-460 xenograft model. (A) Differences in the tumour weight (mg). (B) Percent growth inhibition after treatment. Statistically significant difference (P <0.05) of the combination treatment of doxorubicin and P276-00 compared with the control was seen.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us